#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15052	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2222	673.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1413	1413	C	899	C,T,G	828,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27878	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3491	795.4	0	.	n	.	0	T695C	SNP	695	695	T	997	997	C	859	C,A	806,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27878	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3491	795.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1639	1639	A	893	A,G	838,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27878	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3491	795.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2273	2273	C	887	C,T	832,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27878	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3491	795.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2899	2899	T	851	T,C	641,164	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27878	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3491	795.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2347	2347	A	868	A	836	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2264	folP	852	852	100.0	folP.l15.c4.ctg.1	1687	133.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1065	1067	AGC	211;213;216	A;G;C	203;204;203	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5584	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	163.6	1	SNP	p	S91F	0	.	.	271	273	TCC	533	535	TCC	197;200;204	T;C;C	182;189;188	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5584	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	163.6	1	SNP	p	D95N	0	.	.	283	285	GAC	545	547	GAC	206;207;207	G;A;C	190;189;190	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5584	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3401	163.6	1	SNP	p	D95G	0	.	.	283	285	GAC	545	547	GAC	206;207;207	G;A;C	190;189;190	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1242	mtrR	633	633	97.47	mtrR.l15.c4.ctg.1	1223	101.4	0	.	p	.	0	D79N	NONSYN	235	237	GAT	572	574	AAT	168;169;168	A;A;T	163;165;163	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1242	mtrR	633	633	97.47	mtrR.l15.c4.ctg.1	1223	101.4	0	.	p	.	0	A86T	NONSYN	256	258	GCG	593	595	ACG	186;189;196	A;C;G	172;180;186	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1242	mtrR	633	633	97.47	mtrR.l15.c4.ctg.1	1223	101.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	650	652	CAC	195;195;197	C;A;C	183;181;185	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1242	mtrR	633	633	97.47	mtrR.l15.c4.ctg.1	1223	101.4	0	.	p	.	0	S183N	NONSYN	547	549	AGT	884	886	AAT	64;66;65	A;A;T	59;61;60	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1242	mtrR	633	633	97.47	mtrR.l15.c4.ctg.1	1223	101.4	0	.	p	.	0	M197I	NONSYN	589	591	ATG	926	928	ATA	72;73;75	A;T;A	65;65;68	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1242	mtrR	633	633	97.47	mtrR.l15.c4.ctg.1	1223	101.4	1	SNP	p	G45D	0	.	.	133	135	GGC	470	472	GGC	222;220;222	G;G;C	201;200;201	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5488	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2726	199.7	1	SNP	p	D86N	0	.	.	256	258	GAC	449	451	GAC	195;197;200	G;A;C,A	183;182;184,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5488	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2726	199.7	1	SNP	p	S87I	0	.	.	259	261	AGT	452	454	AGT	202;203;203	A;G;T	188;187;187	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5488	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2726	199.7	1	SNP	p	S87W	0	.	.	259	261	AGT	452	454	AGT	202;203;203	A;G;T	188;187;187	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5488	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2726	199.7	1	SNP	p	S87R	0	.	.	259	261	AGT	452	454	AGT	202;203;203	A;G;T	188;187;187	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5488	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2726	199.7	1	SNP	p	S88P	0	.	.	262	264	TCC	455	457	TCC	208;206;205	T;C,T;C	192;187,1;188	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4544	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2711	167.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1625	1627	GGC	241;239;236	G;G;C,T	220;217;212,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1268	1270	GCA	246;244;243	G;C,T;A	231;225,1;231	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1271	1273	ATC	243;243;244	A;T;C	229;229;230	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1283	1285	GTG	243;238;239	G;T;G	228;226;225	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1283	1285	GTG	243;238;239	G;T;G	228;226;225	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1787	1789	ACC	197;196;195	A;C;C	181;183;184	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1841	1843	GCG	209;207;209	G;C,G;G	191;173,1;178	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1841	1843	GCG	209;207;209	G;C,G;G	191;173,1;178	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1964	1966	GGC	168;167;171	G;G;C	159;159;163	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1973	1975	GGC	161;160;160	G;G;C	155;153;154	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4018	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2400	166.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1991	1993	CCG	144;147;152	C,G;C,G;G	108,3;110,2;115	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5862	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3042	192.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2400	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1904	125.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	587	587	C	179	C	163	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	238	porB1a	984	297	90.7	porB1a.l15.c30.ctg.2	491	21.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	213	215	AAT	14;14;14	A;A;T	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	238	porB1a	984	297	90.7	porB1a.l15.c30.ctg.2	491	21.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	216	218	AAT	14;14;14	A;A;T	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	238	porB1a	984	297	90.7	porB1a.l15.c30.ctg.2	491	21.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	240	242	GCA	16;16;16	G;C;A	16;16;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	238	porB1a	984	297	90.7	porB1a.l15.c30.ctg.2	491	21.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	263	265	GTA	17;17;16	G;T;A	17;17;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	238	porB1a	984	297	90.7	porB1a.l15.c30.ctg.2	491	21.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	272	272	A	17	A	17	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	0	.	p	.	0	I45V	NONSYN	133	135	ATT	377	379	GTT	211;206;203	G;T;T	200;193;191	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	0	.	p	.	0	I75V	NONSYN	223	225	ATT	467	469	GTT	188;187;189	G;T;T	176;170;175	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	0	.	p	.	0	S89T	NONSYN	265	267	AGC	509	511	ACC	217;218;221	A;C;C	188;196;198	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	0	.	p	.	0	I98V	NONSYN	292	294	ATC	536	538	GTC	228;230;228	G;T;C,A	208;206;208,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	0	.	p	.	0	Y213_N214insRYAY	INS	637	637	T	881	881	T	258	T	241	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	0	.	p	.	0	R272H	NONSYN	814	816	CGT	1070	1072	CAT	242;242;245	C;A;T	224;225;226	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	1	SNP	p	G120K	1	.	.	358	360	AAG	602	604	AAG	245;242;243	A;A;G	232;229;229	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	1	SNP	p	N121D	0	.	.	361	363	AAC	605	607	AAC	243;243;240	A;A;C	228;229;227	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2832	porB1b	1038	1038	98.29	porB1b.l15.c17.ctg.1	1434	196.2	1	SNP	p	A121N	1	.	.	361	363	AAC	605	607	AAC	243;243;240	A;A;C	228;229;227	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10614	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4853	218.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1993	1995	AAT	218;218;220	A;A;T	212;211;211	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1184	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1068	110.4	1	SNP	p	V57M	1	.	.	169	171	ATG	564	566	ATG	252;250;248	A;T;G	235;232;232	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
